Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975339 | 0.86 | MRGPRX4 (0.70) | MRGPRX4HTR6SLC6A4PDCD1CD274 | |
| SCHEMBL14548608 | 0.84 | MRGPRX4 (0.51) | MRGPRX4HTR6SLC6A4XDHPDCD1 | |
| SCHEMBL21340514 | 0.82 | FFAR1 (0.56) | MRGPRX4MAOBFFAR1FFAR4 | |
| SCHEMBL6979978 | 0.81 | FFAR4 (0.54) | MRGPRX4FFAR4 | |
| SCHEMBL6980764 | 0.80 | MRGPRX4 (0.54) | MRGPRX4HTR6MAOB | |
| SCHEMBL6979387 | 0.74 | FFAR1 (0.42) | MAOBFFAR1 | |
| SCHEMBL20630916 | 0.74 | HTR6 (0.62) | MRGPRX4HTR6SLC6A4MAOBPDCD1 | |
| SCHEMBL22469778 | 0.74 | MRGPRX4 (0.76) | MRGPRX4HTR6SLC6A4MAOBPDCD1 | |
| SCHEMBL13814708 | 0.74 | ALDH1A1 (0.47) | HTR6SLC6A4 | |
| SCHEMBL31568445 | 0.74 | MRGPRX4 (0.76) | MRGPRX4HTR6SLC6A4MAOBPDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | MRGPRX4 952/4885HTR6 755/4885SLC6A4 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.